Home Bancorp announced that CEO John W. Bordelon will retire effective January 8, 2027, after over 45 years with the company. Bordelon will remain Chairman and on the boards to support leadership continuity. Darren E. Guidry, currently President since July 2026, will become CEO upon Bordelon's retirement. Guidry has been with the company since 1993 and is expected to lead Home Bancorp into its next growth phase with a focus on strategic priorities and long-term shareholder value.
Home Bancorp's CEO retirement and leadership transition provide context for financial sector activity. For readers following Financials, here is Pluang's market snapshot as of Oct 20, 2026 03:02 WIB: Of 142 priced US Financials stocks on Pluang, 42 rose and 99 fell. Notable movers include GEMI at USD 3.23, down 9.52% with a typical hold time of 15 days and Pluang order activity at 56% Sell / 44% Buy; COIN at USD 172.94, down 5.91% with a typical hold time of 79 days and order activity 18% Sell / 82% Buy; and UPST at USD 23.35, down 5.66% with a typical hold time of 39 days.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
